Seminars in nuclear medicine最新文献

{"title":"The Future Direction of Women in Nuclear Medicine and Nuclear Medicine in Women's Health","authors":"Laura Evangelista MD, PhD ,&nbsp;Priscilla Guglielmo MD ,&nbsp;Agata Pietrzak PhD ,&nbsp;Alexandra Maria Lazar MD ,&nbsp;Luca Urso MD ,&nbsp;Atena Aghaee MD ,&nbsp;Elisabeth Eppard PhD","doi":"10.1053/j.semnuclmed.2023.12.001","DOIUrl":"10.1053/j.semnuclmed.2023.12.001","url":null,"abstract":"<div><p><span><span>This work discusses the role of Nuclear Medicine<span> for women's health, the role of women in the development of this emerging field and the various issues which arise from both. It emphasizes the importance of young women and their competing needs due to factors like pregnancy and work-related challenges. The objectives of this overview include improving </span></span>imaging techniques, preserving fertility during cancer treatment, diagnosing pelvic and uterine conditions, developing </span>radiopharmaceuticals for women's health, protecting female employees in Nuclear Medicine, and considering the role of artificial intelligence.</p></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"54 2","pages":"Pages 302-310"},"PeriodicalIF":4.9,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139460401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nuclear Medicine and Molecular Imaging Applications in Gynecologic Malignancies: A Comprehensive Review","authors":"Tasnim Khessib MD ,&nbsp;Priyanka Jha MBBS ,&nbsp;Guido A. Davidzon MD ,&nbsp;Andrei Iagaru MD ,&nbsp;Jagruti Shah MBBS","doi":"10.1053/j.semnuclmed.2024.01.003","DOIUrl":"10.1053/j.semnuclmed.2024.01.003","url":null,"abstract":"<div><p>Gynecologic malignancies, consisting of endometrial, cervical, ovarian, vulvar, and vaginal cancers, pose significant diagnostic and management challenges due to their complex anatomic location and potential for rapid progression. These tumors cause substantial morbidity and mortality, often because of their delayed diagnosis and treatment. An estimated 19% of newly diagnosed cancers among women are gynecologic in origin. In recent years, there has been growing evidence supporting the integration of nuclear medicine imaging modalities in the diagnostic work-up and management of gynecologic cancers. The sensitivity of fluorine-18 fluorodeoxyglucose positron emission tomography (¹⁸F-FDG PET) combined with the anatomical specificity of computed tomography (CT) and magnetic resonance imaging (MRI) allows for the hybrid evaluation of metabolic activity and structural abnormalities that has become an indispensable tool in oncologic imaging. Lymphoscintigraphy, using technetium 99m (^99mTc) based radiotracers along with single photon emission computed tomography/ computed tomography (SPECT/CT), holds a vital role in the identification of sentinel lymph nodes to minimize the surgical morbidity from extensive lymph node dissections. While not yet standard for gynecologic malignancies, promising therapeutic nuclear medicine agents serve as specialized treatment options for patients with advanced or recurrent disease. This article aims to provide a comprehensive review on the nuclear medicine applications in gynecologic malignancies through the following objectives: 1) To describe the role of nuclear medicine in the initial staging, lymph node mapping, response assessment, and recurrence/surveillance imaging of common gynecologic cancers, 2) To review the limitations of ¹⁸F-FDG PET/CT and promising applications of ¹⁸F-FDG PET/MRI in gynecologic malignancy, 3) To underscore the promising theragnostic applications of nuclear medicine, 4) To highlight the current role of nuclear medicine imaging in gynecologic cancers as per the National Comprehensive Cancer Network (NCCN), European Society of Surgical Oncology (ESGO), and European Society of Medical Oncology (ESMO) guidelines.</p></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"54 2","pages":"Pages 270-292"},"PeriodicalIF":4.9,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139717894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurological Disorders and Women's Health: Contribution of Molecular Neuroimaging Techniques","authors":"Ozgul Ekmekcioglu MD ,&nbsp;Nathalie L. Albert MD ,&nbsp;Kathrin Heinrich MD ,&nbsp;Nelleke Tolboom MD ,&nbsp;Donatienne Van Weehaeghe MD, PhD ,&nbsp;Tatiana Traub-Weidinger MD ,&nbsp;Lutfiye Ozlem Atay MD ,&nbsp;Valentina Garibotto MD ,&nbsp;Silvia Morbelli MD","doi":"10.1053/j.semnuclmed.2024.01.010","DOIUrl":"10.1053/j.semnuclmed.2024.01.010","url":null,"abstract":"<div><p>Sex differences in brain physiology and the mechanisms of drug action have been extensively reported. These biological variances, from structure to hormonal and genetic aspects, can profoundly influence healthy functioning and disease mechanisms and might have implications for treatment and drug development. Molecular neuroimaging techniques may help to disclose sex's impact on brain functioning, as well as the neuropathological changes underpinning several diseases. This narrative review summarizes recent lines of evidence based on PET and SPECT imaging, highlighting sex differences in normal conditions and various neurological disorders.</p></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"54 2","pages":"Pages 237-246"},"PeriodicalIF":4.9,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139747283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [18F]F-FDG Tracers Part II. [18F]F-FLT, [18F]F-FET, [11C]C-MET and Other Less-Commonly Used Radiotracers","authors":"Roya Eisazadeh MD, FEBNM ,&nbsp;Malihe Shahbazi-Akbari MD ,&nbsp;Seyed Ali Mirshahvalad MD, MPH, FEBNM ,&nbsp;Christian Pirich MD, PhD ,&nbsp;Mohsen Beheshti MD, FEBNM, FASNC","doi":"10.1053/j.semnuclmed.2024.01.002","DOIUrl":"10.1053/j.semnuclmed.2024.01.002","url":null,"abstract":"<div><p>Following the previous part of the narrative review on artificial intelligence (AI) applications in positron emission tomography (PET) using tracers rather than ¹⁸F-fluorodeoxyglucose ([¹⁸F]F-FDG), in this part we review the impact of PET-derived radiomics data on the diagnostic performance of other PET radiotracers, ¹⁸F-O-(2-fluoroethyl)-L-tyrosine ([¹⁸F]F-FET), ¹⁸F-Fluorothymidine ([¹⁸F]F-FLT) and ¹¹C-Methionine ([¹¹C]C-MET). [¹⁸F]F-FET-PET, using an artificial amino acid taken up into upregulated tumoral cells, showed potential in lesion detection and tumor characterization, especially with its ability to reflect glioma heterogeneity. [¹⁸F]F-FET-PET-derived textural features appeared to have the potential to reveal considerable information for accurate delineation for guiding biopsy and treatment, differentiate between low-grade and high-grade glioma and related wild-type genotypes, and distinguish pseudoprogression from true progression. In addition, models built using clinical parameters and [¹⁸F]F-FET-PET-derived radiomics features showed acceptable results for survival stratification of glioblastoma patients. [¹⁸F]F-FLT-PET-based characteristics also showed potential in evaluating glioma patients, correlating with Ki-67 and patient prognosis. AI-based PET-volumetry using this radiotracer as a proliferation marker also revealed promising preliminary results in terms of guide-targeting bone marrow-preserving adaptive radiation therapy. Similar to [¹⁸F]F-FET, the other amino acid tracer which reflects cellular proliferation, [¹¹C]C-MET, has also shown acceptable performance in predicting tumor grade, distinguishing brain tumor recurrence from radiation necrosis, and treatment monitoring by PET-derived radiomics models.</p><p>In addition, PET-derived radiomics features of various radiotracers such as [¹⁸F]F-DOPA, [¹⁸F]F-FACBC, [¹⁸F]F-NaF, [⁶⁸Ga]Ga-CXCR-4 and [¹⁸F]F-FMISO may also provide useful information for tumor characterization and predict of disease outcome.</p><p>In conclusion, AI using tracers beyond [¹⁸F]F-FDG could improve the diagnostic performance of PET-imaging for specific indications and help clinicians in their daily routine by providing features that are often not detectable by the naked eye.</p></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"54 2","pages":"Pages 293-301"},"PeriodicalIF":4.9,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0001299824000023/pdfft?md5=3c21bb99ce86211ab2191ed6c03b81bd&pid=1-s2.0-S0001299824000023-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139707777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter From the Editors","authors":"Kirsten Bouchelouche,&nbsp;M Michael Sathekge","doi":"10.1053/j.semnuclmed.2023.11.006","DOIUrl":"https://doi.org/10.1053/j.semnuclmed.2023.11.006","url":null,"abstract":"","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"54 1","pages":"Pages 1-3"},"PeriodicalIF":4.9,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138490258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What Role Does PET/MRI Play in Musculoskeletal Disorders?","authors":"Tugce Telli, Mélanie Desaulniers, Thomas Pyka, Federico Caobelli, Sophia Forstmann, Lale Umutlu, Wolfgang P Fendler, Axel Rominger, Ken Herrmann, Robert Seifert","doi":"10.1053/j.semnuclmed.2023.11.004","DOIUrl":"https://doi.org/10.1053/j.semnuclmed.2023.11.004","url":null,"abstract":"<p><p>Musculoskeletal disorders of nononcological origin are one of the most frequent reasons for consultation. Patients suffering from musculoskeletal disorders also consult more than once for the same reason. This results in multiple clinical follow-ups after several radiological and serum examinations, the main ones including X-rays targeting the painful anatomical region and inflammatory serum parameters. As part of their work up, patients suffering from musculoskeletal disorders often require multisequence, multi-parameter MRI. PET/MRI is a promising imaging modality for their diagnosis, with the added advantage of being able to be performed in a single visit. PET/MRI is particularly useful for diagnosing osteomyelitis, spondylodiscitis, arthritis, many pediatric pathologies, and a wide range of other musculoskeletal pathologies. PET/MRI is already used to diagnose malignant bone tumors such as osteosarcoma. However, current knowledge of the indications for PET/MRI in nononcological musculoskeletal disorders is based on studies involving only a few patients. This review focuses on the usefulness of PET/MRI for diagnosing nononcological musculoskeletal disorders.</p>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2023-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138478517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Targets for Molecular Imaging of Inflammatory Processes of Carotid Atherosclerosis: A Systematic Review","authors":"","doi":"10.1053/j.semnuclmed.2023.10.004","DOIUrl":"10.1053/j.semnuclmed.2023.10.004","url":null,"abstract":"<div><p><span>Computed tomography angiography<span> (CTA), magnetic resonance angiography (MRA) and </span></span>¹⁸<span>F-FDG-PET have proven clinical value when evaluating patients with carotid atherosclerosis<span>. In this systematic review<span><span>, we will focus on the role of novel molecular imaging </span>tracers<span> in that assessment and their potential strengths to stratify stroke risk. We systematically searched PubMed, Embase, the Web of Science Core Collection, and Cochrane Library for articles reporting on molecular imaging to noninvasively detect or characterize inflammation in carotid atherosclerosis. As our focus was on nonclassical novel targets, we omitted reports solely on </span></span></span></span>¹⁸F-FDG and ¹⁸<span>F-NaF. We summarized and mapped the selected studies to provide an overview of the current clinical development in molecular imaging in relation to risk factors, imaging and histological findings, diagnostic and prognostic performance. We identified 20 articles in which the utilized tracers to visualize carotid wall inflammation were somatostatin<span><span> subtype-2- (SST2-) (n = 5), CXC-motif chemokine receptor 4- (CXCR4-) (n = 3), </span>translocator<span> protein- (TSPO-) (n = 2) and aVβ3 integrin-ligands (n = 2) and choline-tracers (n = 2). Tracer uptake correlated with traditional cardiovascular risk factors, that is, age, gender, diabetes, hypercholesterolemia, and hypertension as well as prior cardiovascular disease. We identified discrepancies between tracer uptake and grade of stenosis, plaque calcification, and </span></span></span>¹⁸<span><span>F-FDG uptake, suggesting the importance of alternative characterization of atherosclerosis beyond classical neuroimaging features. Immunohistochemical analysis linked tracer uptake to markers of macrophage infiltration and neovascularization. Symptomatic carotid arteries showed higher uptake compared to asymptomatic (including </span>contralateral<span>, nonculprit) arteries. Some studies demonstrated a potential role of these novel molecular imaging as a specific intermediary (bio)marker for outcome. Several novel tracers show promise for identification of high-risk plaque inflammation. Based on the current evidence we cautiously propose the SST2-ligands and the choline radiotracers as viable candidates for larger prospective longitudinal outcome studies to evaluate their predictive use in clinical practice.</span></span></p></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"54 5","pages":"Pages 658-673"},"PeriodicalIF":4.6,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138299887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards a More Inclusive Future: A Comprehensive Assessment of Gender Diversity in Nuclear Medicine Education, Training and Workforce","authors":"Anita Brink MD, PhD ,&nbsp;Ora Israel MD, PhD ,&nbsp;Helen Nadel MD, PhD ,&nbsp;Manuela Arevalo-Pardo LLB ,&nbsp;Oleksandr Kalinchuk MS ,&nbsp;Enrique Estrada-Lobato MD ,&nbsp;Maria Naydenova MSc, MBA ,&nbsp;Milena Drace BA, MSc ,&nbsp;Diana Paez MD, MsEd","doi":"10.1053/j.semnuclmed.2023.10.006","DOIUrl":"10.1053/j.semnuclmed.2023.10.006","url":null,"abstract":"<div><p><span><span>The field of nuclear medicine<span> has undergone remarkable advances, particularly with the introduction of new devices, radionuclides for imaging and </span></span>therapy<span>, new clinical applications, and emergence of medical evidence. As this dynamic field continues its rapid expansion, there is an urgent need to increase the number of well-trained professionals globally. Consequently, advocating for nuclear medicine as a thriving field of study and work for women becomes paramount in ensuring the establishment of a robust workforce capable of meeting the growing demands. True gender equality will only be achieved when there is equal representation across the spectrum of the nuclear medicine professions<span>, including nuclear medicine technologists, radiopharmacists, radiochemist, medical physicists, </span></span></span>nuclear medicine physicians<span>, administrators, academics, and leaders. Currently, the workforce exhibits an imbalance, with females predominating among nuclear medicine technologists, while the number of female physicians, and those in leadership positions remains comparatively lower. There are various factors which contribute to the existing inequities. Societal expectations often impose traditional gender roles that somehow discourage women from pursuing a career in the science, technology, and mathematics (STEM) fields, including nuclear medicine. Additionally, prevailing unequal work conditions and gender biases within the workplace can create barriers that hinder women's professional growth and development. Ways of addressing inequalities includes ensuring female participation at all levels of education and training and promoting the field at undergraduate level in medical school. Mentorship programs have demonstrated great success in guiding and supporting women at various stages of their careers. Therefore, there is a need for their expansion and enhancement. Furthermore, female role models play a pivotal role in shattering gender stereotypes and inspiring other women to pursue careers in nuclear medicine and its related fields. By addressing the existing imbalances and fostering an environment that actively encourages and supports women, we can harness the full potential of all professionals, thus ensuring the ongoing progress and advancement of nuclear medicine.</span></p></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"54 2","pages":"Pages 184-190"},"PeriodicalIF":4.9,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138177235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Practical Guide to the Pearls and Pitfalls of PSMA PET Imaging","authors":"Andrew F. Voter MD, PhD ,&nbsp;Rudolf A. Werner MD ,&nbsp;Hatice Savas MD ,&nbsp;Andrei Gafita MD ,&nbsp;Ashley E. Ross MD, PhD ,&nbsp;Michael A. Gorin MD ,&nbsp;Lilja B. Solnes MD, MBA ,&nbsp;Martin G. Pomper MD, PhD ,&nbsp;Steven P. Rowe MD, PhD ,&nbsp;Sara Sheikhbahaei MD, PhD","doi":"10.1053/j.semnuclmed.2023.11.001","DOIUrl":"10.1053/j.semnuclmed.2023.11.001","url":null,"abstract":"<div><p><span>Prostate-specific membrane antigen (PSMA)-targeted PET agents have revolutionized the care of patients with prostate cancer<span>, supplanting traditional methods of imaging prostate cancer, and improving the selection and delivery of therapies. This has led to a rapid expansion in both the number of PSMA PET scans performed and the imaging specialists required to interpret those scans. To aid those imagers and clinicians who are new to the interpretation of PSMA PET, this review provides an overview of the interpretation of PSMA PET/CT imaging and pearls for overcoming commonly encountered pitfalls. We discuss the physiologic distribution of the clinically available PSMA-targeted </span></span>radiotracers, the commonly encountered patterns of prostate cancer spread, as well as the benign and malignant mimics of prostate cancer. Additionally, we review the standardized PSMA PET reporting systems and the role of PSMA in selecting appropriate patients for PSMA-targeted therapies.</p></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"54 1","pages":"Pages 119-131"},"PeriodicalIF":4.9,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSMA PET/CT Versus mpMRI for the Detection of Clinically Significant Prostate Cancer: An Updated Overview","authors":"Matteo Caracciolo ,&nbsp;Angelo Castello ,&nbsp;Egesta Lopci MD, PhD","doi":"10.1053/j.semnuclmed.2023.10.002","DOIUrl":"10.1053/j.semnuclmed.2023.10.002","url":null,"abstract":"<div><p><span>In the last years, PSMA-PET imaging and multiparametric MRI (mpMRI) have improved the clinical management of prostate cancer (PCa) patients. Currently, mpMRI is recommended by the EAU (European Association of Urology) guidelines for the primary diagnosis of PCa, whereas PSMA-PET is reserved for disease staging, particularly in high risk localized or locally advanced disease, as well as for </span>biochemical recurrence after surgery. Nevertheless, several studies have explored the added value of PSMA-PET in other clinical scenarios, including primary diagnosis and especially for the detection of clinically significant PCa (csPCa). In the present contribution, we will provide an overview and an update on the current literature on imaging detection of csPCa, with a particular focus on mpMRI, PSMA-PET and their comparison.</p></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"54 1","pages":"Pages 30-38"},"PeriodicalIF":4.9,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89719453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}